This Article Full Text Full Text (PDF) All Versions of this Article: 39/3/850    most recent STROKEAHA.107.493601v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Diringer, M. N. Articles by Broderick, J. P. PubMed PubMed Citation Articles by Diringer, M. N. Articles by Broderick, J. P. Pubmed/NCBI databases Substance via MeSH Related Collections Other Stroke Treatment - Medical Arterial thrombosis Deep vein thrombosis Acute Cerebral Hemorrhage Acute Cerebral Infarction

(Stroke. 2008;39:850.)
© 2008 American Heart Association, Inc.

Original Contributions

Risk of Thromboembolic Events in Controlled Trials of rFVIIa in Spontaneous Intracerebral Hemorrhage

Michael N. Diringer, MD; Brett E. Skolnick, PhD; Stephan A. Mayer, MD; Thorsten Steiner, MD; Stephen M. Davis, MD; Nikolai C. Brun, MD, PhD Joseph P. Broderick, MD

From the Department of Neurology/Neurosurgery Intensive Care Unit (M.N.D.), Washington University School of Medicine, St Louis, Mo; Novo Nordisk Inc (B.E.S.), Princeton, NJ; the Departments of Neurology and Neurosurgery, Columbia University College of Physicians and Surgeons (S.A.M.), New York, NY; the Department of Neurology (T.S.), University of Heidelberg, Germany; the Department of Neurology (S.M.D.), Royal Melbourne Hospital/University of Melbourne, Parkville, Australia; Novo Nordisk, Bagsværd (N.C.B.), Denmark; and the Department of Neurology (J.P.B.), The Neuroscience Institute, University of Cincinnati Medical Center, Cincinnati, Ohio.

Correspondence to Michael N Diringer, MD, Department of Neurology, Campus Box 8111, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63110. E-mail diringerm{at}neuro.wustl.edu

Background and Purpose— Recombinant activated factor VII (rFVIIa) reduces hematoma expansion and improves outcome after intracerebral hemorrhage (ICH), with an apparent increase in nonfatal thromboembolic events (TEs) with higher doses. Despite low incidences of such events in rFVIIa-treated hemophiliacs, the frequency in older patients with more atherosclerosis and immobility has yet to be defined.

Methods— Data were pooled from 3 randomized placebo-controlled studies in patients diagnosed within 3 hours of spontaneous ICH who received a single dose of rFVIIa (5 to 160 µg/kg; n=371) or placebo (n=115). Clinical/laboratory evaluations, lower extremity Doppler studies, and 72-hour CT scans were used to monitor for TEs. Adverse events occurring while hospitalized and serious events occurring through day 90 were carefully reviewed.

Results— There was no overall increase in risk of total TEs in rFVIIa-treated patents; however, there were more arterial, but not venous, TEs in the high dose group (120 to 160 µg/kg) compared with placebo (5.4% versus 1.7%; P=0.13). Arterial events occurring within 7 days of drug administration classified as possibly or probably associated with study drug included myocardial ischemia (n=9, 8 were non–ST-segment elevation and non–Q-wave events; 2 of the 9 had sequelae) and ischemic stroke (n=9, 4 of which had likely causes other than rFVIIa). Regression analysis identified high doses (120 to 160 µg/kg) of rFVIIa as the only factor associated with arterial TEs (odds ratio=6.75; P=0.02).

Conclusions— There appears to be a increased risk of arterial TEs associated with higher doses of rFVIIa in ICH patients as compared with placebo. Further studies are underway to identify specific factors associated with these events and to define the dose that maximizes benefit and minimizes risk.

Key Words: clinical trials • intracerebral hemorrhage • recombinant activated factor VII (rFVIIa) • thromboembolic events

This article has been cited by other articles:

				H. Hallevi, N. R. Gonzales, A. D. Barreto, S. Martin-Schild, K. C. Albright, E. A. Noser, K. Illoh, A. M. Khaja, T. Allison, M. A. Escobar, et al. Response to Letter by Steiner et al Stroke, July 1, 2008; 39(7): e119 - e120. [Full Text] [PDF]